SCHEMBL16015696

SCHEMBL16015696

COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)COC(=O)CCC(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 9/20 0.80
▸ THRB P10828 9/20 0.80
▸ KMT2A Q03164 9/20 0.80
▸ RECQL P46063 7/20 0.80
▸ BLM P54132 7/20 0.80
▸ BRCA1 P38398 6/20 0.80
▸ HIF1A Q16665 6/20 0.80
▸ SMN1; SMN2 Q16637 6/20 0.80
▸ TDP1 Q9NUW8 6/20 0.80
▸ MAPT P10636 6/20 0.80
▸ TOP2A P11388 4/20 0.80
▸ MAPK1 P28482 4/20 0.80
▸ STAT6 P42226 4/20 0.80
▸ HTT P42858 4/20 0.80
▸ CHRM1 P11229 3/20 0.80
▸ TBXA2R P21731 3/20 0.80
▸ KDM4E B2RXH2 3/20 0.80
▸ ALDH1A1 P00352 3/20 0.80
▸ ABCB1 P08183 3/20 0.80
▸ FYN P06241 2/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26387964 1.00 MEN1 (0.80) MEN1THRBKMT2ARECQLBLM
SCHEMBL14867452 0.97 MEN1 (0.84) MEN1THRBKMT2ARECQLBLM
SCHEMBL15682452 0.96 MEN1 (0.78) MEN1THRBKMT2ARECQLBLM
SCHEMBL14524965 0.96 MEN1 (0.78) MEN1THRBKMT2ARECQLBLM
SCHEMBL10138466 0.94 MEN1 (0.81) MEN1THRBKMT2ARECQLBLM
SCHEMBL12462937 0.94 MEN1 (0.80) MEN1THRBKMT2ARECQLBLM
SCHEMBL15382713 0.94 MEN1 (0.74) MEN1THRBKMT2ARECQLBLM
SCHEMBL15682451 0.94 MEN1 (0.74) MEN1THRBKMT2ARECQLBLM
SCHEMBL14524940 0.94 MEN1 (0.74) MEN1THRBKMT2ARECQLBLM
SCHEMBL13675027 0.93 MEN1 (0.79) MEN1THRBKMT2ARECQLBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150038429-A1 ETOPOSIDE AND DOXORUBICIN CONJUGATES FOR DRUG DELIVERY ANGIOCHEM INC. (CA) 2015-02-05 — — US disclosed
US-8828925-B2 Etoposide and doxorubicin conjugates for drug delivery ANGIOCHEM INC. (CA) 2014-09-09 — — US disclosed
US-20120135914-A1 ETOPOSIDE AND DOXORUBICIN CONJUGATES FOR DRUG DELIVERY ANGIOCHEM INC. (CA) 2012-05-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135914-A1 ETOPOSIDE AND DOXORUBICIN CONJUGATES FOR DRUG DELIVERY GLS, AQP4, ABCB1 MEN1 582/4885THRB 4818/4885KMT2A 527/4885
US-20150038429-A1 ETOPOSIDE AND DOXORUBICIN CONJUGATES FOR DRUG DELIVERY GLS, AQP4, ABCB1 MEN1 582/4885THRB 4818/4885KMT2A 527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback